| Similar Articles |
|---|
 |
The Motley Fool
August 10, 2010
Jeremy Phillips |
Technically, Netflix Is a Buy Want to buy Netflix based on technical merits today? Technically, odds are that you should flip and sell Netflix sometime very soon.   |
The Motley Fool
August 9, 2010
Jeremy Phillips |
Technically, priceline.com Is a Buy Assuming you pay attention to lines on a graph. |
The Motley Fool
August 10, 2010
Jeremy Phillips |
Technically, Apple Is a Buy Buy Apple, assuming you pay attention to technical analysis. |
The Motley Fool
August 9, 2010
Jeremy Phillips |
Technically, IBM Is a Buy Assuming you pay attention to lines on a graph. |
The Motley Fool
August 6, 2010
Jeremy Phillips |
Technically, Linn Energy Is a Buy It's time to buy Linn Energy assuming you pay attention to lines on a graph, but we recommend choosing companies based on more important factors. |
The Motley Fool
August 10, 2010
Jeremy Phillips |
Technically, NVIDIA Is a Sell NVIDIA has led the graphics card space for years, but has faced recent ominous signs. |
The Motley Fool
July 30, 2010
Jeremy Phillips |
Technically, YRC Worldwide Is a Buy Looking at the indicators, you should buy YRC Worldwide. |
The Motley Fool
August 11, 2010
Jeremy Phillips |
Technically, SanDisk Is a Buy Assuming you pay attention to technical analysts. |
The Motley Fool
August 2, 2010
Jeremy Phillips |
Technically, Level 3 Communications Is a Buy According to technical analysis, you should be buying Level 3 right now. But not so fast. |
The Motley Fool
August 11, 2010
Jeremy Phillips |
Technically, Cree Is a Sell But here's no stopping the march of LED lighting, and that's the way Cree likes it. |
The Motley Fool
August 6, 2010
Jeremy Phillips |
Technically, Annaly Capital Is a Sell Technically, you should sell Annaly Capital right now. But, the amount of trading in most technical analysis schemes eats away at profits from good companies like this. Read why. |
The Motley Fool
August 9, 2010
Jeremy Phillips |
Technically, Ambac Financial Is a Buy Assuming you pay attention to lines on a graph. |
The Motley Fool
August 9, 2010
Jeremy Phillips |
Technically, Hewlett-Packard Is a Sell Sell this, assuming you pay attention to lines on a graph. |
The Motley Fool
August 6, 2010
Jeremy Phillips |
Technically, Frontier Is a Buy We examined Frontier using Moving Average Convergence-Divergence, which is one of the most popular and long-used technical analysis indicators. Technically, the company is a buy, but we disagree. Here's why. |
The Motley Fool
July 30, 2010 |
Technically, ATP Oil & Gas Is a Buy Assuming you listen only to the cold, hard numbers. |
The Motley Fool
July 29, 2010 |
Technically, STEC Is a Buy Is that reason enough? |
The Motley Fool
August 2, 2010
Jeremy Phillips |
Technically, Brocade Is a Buy Technically, you should buy Brocade Communications right now. |
The Motley Fool
July 30, 2010
Jeremy Phillips |
Technically, JDS Uniphase Is a Buy The signal line crossover says you should buy JDS Uniphase right now. But you might not want to listen. |
The Motley Fool
July 29, 2010 |
Technically, CenturyLink Is a Buy Analyzing the vagaries of technical analysis. |
The Motley Fool
July 30, 2010
Jeremy Phillips |
Technically, RF Micro Devices Is a Buy Technically, you should buy RF Micro Devices right now. But you may want to pay attention to other things. |
The Motley Fool
August 9, 2010
Jeremy Phillips |
Technically, Sirius XM Radio Is a Buy Buy Sirius XM, assuming you pay attention to lines on a graph. |
The Motley Fool
August 6, 2010
Jeremy Phillips |
Technically, Altria Is a Buy Technically, you should buy Altria right now. |
The Motley Fool
December 5, 2008
Brian Orelli |
Be Kind to MannKind MannKind has good data on its inhaled insulin drug, but will the FDA approve of it and will diabetics buy it? |
The Motley Fool
December 27, 2011
Brian Orelli |
2011 No Dreamboat for MannKind An FDA rejection and a long wait is a bad combination. |
The Motley Fool
June 11, 2010
Brian Orelli |
Double-Digit Pop Because the Drug Still Works? Developments at Mannkind's shareholder meeting send stock soaring. |
The Motley Fool
March 16, 2010
Brian Orelli |
How to Lose $114 Million in One Day You've got to be a very trusting investor to buy shares in pharmaceutical company, MannKind. |
The Motley Fool
August 12, 2011
Evan Niu |
One Small Step for Afrezza, One Giant Leap for MannKind Afrezza makes headway toward FDA approval. |
The Motley Fool
April 14, 2008
Brian Lawler |
MannKind Gets Smacked by Big Brother's Bad News Bad news for a competitor sinks MannKind shares. |
The Motley Fool
June 19, 2009
Robert Steyer |
MannKind Needs More Leaps Getting FDA approval for its inhaled-insulin product is only one hurdle for this start-up pharmaceutical. |
The Motley Fool
May 6, 2008
Brian Lawler |
MannKind Moves Ahead The pharmaceutical awaits pivotal data on its lead drug Technosphere. |
The Motley Fool
June 29, 2011
Brian Orelli |
So Much Insulin, So Little Use for It MannKind settles its supply agreement with Merck. |
The Motley Fool
January 16, 2008
Brian Lawler |
Another Inhalable Insulin Bites the Dust Novo Nordisk discontinues development of its troubled diabetes treatment and settles its patent infringement lawsuit against Pfizer. Investors, take note. |
The Motley Fool
September 19, 2006
Brian Lawler |
A Long Wait for MannKind The company's inhaled insulin might not reach the market for several years, if it does, but it's a big market. Investors, take note. |
The Motley Fool
July 30, 2010
Brian Orelli |
MannKind: Strengths, Weaknesses, Opportunities, Threats It's all about the inhaled insulin. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
September 22, 2010
Brian Orelli |
Better Buy: Amylin Pharmaceuticals or MannKind? It's a diabetes-drug showdown. |
The Motley Fool
March 6, 2008
Brian Lawler |
2008 Should Make or Break MannKind MannKind updates investors on what to expect this year. |
The Motley Fool
December 28, 2010
Brian Orelli |
Double-Digit Increase! Haven't We Learned Anything? MannKind's investors need a history lesson. |
The Motley Fool
June 27, 2005
Stephen D. Simpson |
Sniffing Out a Possible Diabetes Blockbuster Inhaled insulin has been a Holy Grail of diabetes care. Will it live up to lofty expectations? Pfizer, Sanofi-Aventis, and Lilly are all interesting in their own right as high-quality pharmaceutical companies, and more aggressive investors should take a look at Nektar and Alkermes, as well. |
The Motley Fool
May 22, 2006
Stephen D. Simpson |
Nektar Full of Potential, Risk Can inhaled insulin sales live up to investors' expectations at Nektar Therapeutics? |
The Motley Fool
August 6, 2007
Brian Lawler |
Unhappy Delays for MannKind Two delays for the inhalable insulin developer cause the stock to drop. |
The Motley Fool
January 20, 2011
Brian Orelli |
This Stock Is No Dreamboat The FDA is not kind to MannKind. |
Pharmaceutical Executive
March 1, 2006
Ron Feemster |
Holding Their Breath: Inhaled Insulin Exubera, Pfizer's inhaled-insulin therapy, is carving out a new market for diabetes drugs. Four more companies are looking for their share. |
The Motley Fool
December 31, 2009
Brian Orelli |
2010 FDA Decisions to Watch It's a pivotal year for these drugmakers. |
The Motley Fool
April 10, 2008
Brian Lawler |
Nektar Can't Squeeze Nectar From This Drug Nektar Therapeutics announced that it was putting its inhaled insulin drug, Exubera, to rest. Investors, take note. |
Pharmaceutical Executive
May 1, 2009 |
The Fate of Mannkind Al Mann has sunk almost $1 billion of his own money into a new insulin delivery system. Will FDA be persuaded? |
The Motley Fool
October 19, 2007
Brian Lawler |
The Exubera Winner In its third-quarter earnings report, Pfizer announces it is surrendering the rights to market inhalable-insulin treatment Exubera to developer Nektar Therapeutics. Investors, take note. |
The Motley Fool
May 10, 2011
Brian Orelli |
Waiting for MannKind's Pot of Gold It's going to be awhile. |
The Motley Fool
November 13, 2007
Brian Lawler |
Nektar's New Old Drug Pfizer returns its non-selling inhalable insulin experiment Exubera to Nektar Therapeutics today, along with $135 million in cash. |
Chemistry World
August 12, 2014
Phillip Broadwith |
Sanofi snaps up inhaled insulin license Sanofi has struck a licensing deal with US firm Mannkind to develop and commercialize Mannkind's recently-approved Afrezza inhaled insulin powder for global distribution. |
